[Multicentric clinical proof of a new oral antidiabetic glisoxepide (BS 4231). 1. Establishment of proof and methods].
D000469:Alkaline Phosphatase / Q000097:blood; D001381:Azepines / Q000627:therapeutic use*; D001794:Blood Pressure; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004341:Drug Evaluation; D004361:Drug Tolerance; D004562:Electrocardiography; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008722:Methods; D010080:Oxazoles / Q000627:therapeutic use*; D012107:Research Design; D013223:Statistics as Topic; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D013997:Time Factors
D001381:Azepines; D007004:Hypoglycemic Agents; D010080:Oxazoles; D013453:Sulfonylurea Compounds; D000469:Alkaline Phosphatase
Multizentrische klinische Prüfung des neuen oralen Antidiabetikums Glisoxepid (BS 4231) I. Anlage der Prüfung und deren Methodik